Envigo Appoints Patricia Henahan as New Chief Financial Officer
News Jun 11, 2016
Envigo announced that it has appointed Patricia Henahan to the position of Chief Financial Officer. Ms. Henahan has extensive financial experience in the life sciences sector, including leadership roles at Eli Lilly, AstraZeneca, MedImmune and Hospira. She has strong expertise in financial analysis, strategic planning, R&D and operations, with a history of driving continuous improvement through the teams she has led.
"I am delighted that Pat has decided to join the team at Envigo," said Brian Cass, Chief Executive Officer. "Her background in pharmaceuticals and experience across the R&D process will bring valuable insight to our strategic planning as we continue to position Envigo as a leading provider of contract services and research models globally."
Prior to joining Envigo, Ms Henahan was Vice President of Finance for Hospira’s $3 billion US pharmaceutical business and was a key member of the executive team delivering double digit profit growth during her time there. Previous to that she was Chief Financial Officer of the AstraZeneca Group company IPR Pharmaceuticals. Ms Henahan also served for 10 years as a US Army Captain in the Medical Corps.
Ms. Henahan holds an MBA from The Wharton School at the University of Pennsylvania, a bachelor's degree in Biology from the University of Notre Dame, and is a Six Sigma Black Belt.
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE
Cocaine Use Alters Gene Expression in Brain Reward CircuitsNews
A study in Biological Psychiatry investigates transcriptome-wide alterations in response to cocaine self-administration in mice.
Ipsen and MD Anderson Announce Bench-to-Bedside Cancer Drug Development PartnershipNews
MD Anderson will progress the drug candidate through Phase I clinical development with Ipsen being responsible for further global development and commercialization.READ MORE